Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.35 |
| ▸ | GLS | O94925 | 5/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.34 |
| ▸ | USP2 | O75604 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782544 | 0.92 | CCR2 (0.41) | CCR2KCNH2CYP3A4USP2TSHR | |
| SCHEMBL3786892 | 0.85 | CCR2 (0.36) | CCR2GLSKCNH2SMN1; SMN2GAA | |
| SCHEMBL4128765 | 0.84 | CCR2 (0.38) | CCR2GLSKCNH2CYP3A4USP2 | |
| SCHEMBL3781517 | 0.83 | DRD4 (0.46) | CCR2 | |
| SCHEMBL3787852 | 0.82 | CCR2 (0.37) | CCR2GLSKCNH2CYP3A4USP2 | |
| SCHEMBL3786528 | 0.82 | WNT1 (0.40) | CCR2GLSKCNH2MCHR2 | |
| SCHEMBL3776521 | 0.81 | PARP1 (0.44) | KCNH2TSHRMCHR2 | |
| SCHEMBL3782902 | 0.80 | KCNH2 (0.39) | CCR2GLSKCNH2SMN1; SMN2GAA | |
| SCHEMBL3785872 | 0.80 | CCR2 (0.38) | CCR2GLSKCNH2SMN1; SMN2GAA | |
| SCHEMBL3028961 | 0.79 | CCR2 (0.37) | CCR2GLSKCNH2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | claimed |
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | CCR2 1/4885GLS 922/4885KCNH2 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.